BCHT, always attaching great importance to optimum allocation of R&D and innovation resources, is fully equipped for biological vaccine research and pilot production with laboratories and pilot plants covering totally nearly 8,000 ㎡ and more than 800 sets of various advanced experimental equipment or instruments, and can meet the demands of simultaneous R&D on the virus culture scale-up technology platform, final product and adjuvant technology platform, genetic engineering technology platform, and bacterial vaccine technology platform.